alexa Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
Social & Political Sciences

Social & Political Sciences


Author(s): Sievers EL

Abstract Share this page

Abstract Gemtuzumab ozogamicin (CMA-676, Mylotarg, an antibody-targeted chemotherapy agent, was recently approved by the FDA for the treatment of patients with CD33+ acute myeloid leukaemia (AML) in first relapse who are 60 years of age or older and who are not considered candidates for other types of cytotoxic chemotherapy. In combined Phase II studies of 142 patients with CD33+ AML in first relapse, gemtuzumab ozogamicin monotherapy was associated with a 30\% overall response rate. While treated patients had relatively high incidences of myelosuppression, grade 3 or grade 4 hyperbilirubinaemia (23\%) and elevated hepatic transaminases (17\%), the incidences of grade 3 or grade 4 mucositis (4\%) and infections (28\%) were low compared with what might be expected in association with conventional chemotherapeutic treatment. In contrast with the usual in-patient administration of cytarabine and anthracycline-containing induction regimens, a large number of patients were treated with gemtuzumab ozogamicin as outpatients (38\% and 41\% for the first and second doses, respectively). Two prognostic factors for patients with AML in first relapse, age and duration of complete remission, had relatively little effect on response rates to gemtuzumab ozogamicin. Preliminary data in pediatric patients also suggest the immunoconjugate to be reasonably well tolerated. Studies of gemtuzumab ozogamicin in combination with anthracycline and cytarabine are underway. Gemtuzumab ozogamicin, administered to patients with CD33+ AML in first relapse, has shown overall response rates comparable to conventional agents and a safety profile that appears to be favourable. This article was published in Expert Opin Biol Ther and referenced in Anthropology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • World conference on Ecology and Ecosystems
    September 11-13, 2017 San Antonio, USA
  • 6th International Conference on Forensic Research & Technology
    Sep 18-20, 2017 Houston, USA
  • 2nd World Congress on Health and Medical Sociology
    September 25-26, 2017 Atlanta, Georgia, USA
  • 2nd Experts Meeting on Forensic Psychology and Criminology
    October 02-03, 2017 London, UK

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version